Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Endeavor Biomedicines Inc. manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions. These actions are handled by 2 distinct examiners, meaning each pending action is being reviewed by a different examiner. Prosecution activity spans 2 distinct art units, which indicates that the company's biotechnology innovations are being reviewed by two specialized groups within the USPTO.
SHIAO, YIH-HORNG is the busiest examiner for the portfolio, currently overseeing 1 busiest examiner pending office action. This matching number between 2 pending office actions and 2 distinct examiners shows a decentralized prosecution effort. With 2 pending office actions and 2 distinct examiners involved, the portfolio is managed across multiple USPTO personnel. SHIAO, YIH-HORNG handles 1 busiest examiner pending office action, which is the same number of actions assigned to the other examiner in this portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, YIH-HORNG | 1 | 72.6% | +75.9% |
| TRAN, ERIC | 1 | 69.8% | +19.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19652625 | METHODS OF IMPROVING LUNG FUNCTION | SHIAO, YIH-HORNG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18078655 | METHOD OF TREATING CANCER HAVING AN ACTIVATED HEDGEHOG PATHWAY | TRAN, ERIC | 13d |
| 19652625 | METHODS OF IMPROVING LUNG FUNCTION | SHIAO, YIH-HORNG | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19652625 | METHODS OF IMPROVING LUNG FUNCTION | SHIAO, YIH-HORNG | 1691 | §102§103§112 | Non-Final OA | — | Pending | Apr 20, 2026 |
| 18078655 | METHOD OF TREATING CANCER HAVING AN ACTIVATED HEDGEHOG PATHWAY | TRAN, ERIC | 1629 | §103 | Final Rejection | 13d | Pending | Dec 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEndeavor Biomedicines Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Yih-Horng Shiao has the most, with 1 of Endeavor Biomedicines Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
